News Releases Home Synthetic Biology The History of Synthetic Biology Living Medicines Designing Synthetic Biotic™ Medicines Pipeline + Programs For Patients Our People Leadership Board of Directors Founders and Advisors Join Us Investors + Media Company Overview News & Events News Releases Event Calendar Presentations & Publications Stock Information Corporate Governance Financials Investor Resources Items Per Page 102550 Year None2020201920182017201620152014 March 30, 2020 Synlogic Provides Summary of Impact of COVID-19 on Clinical Program Progress and Operational Activities March 12, 2020 Synlogic Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update March 11, 2020 Synlogic to Present at Chardan's Virtual Microbiome Medicines Summit March 5, 2020 Synlogic Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast February 18, 2020 Synlogic Announces Participation in Upcoming Investor Conferences January 30, 2020 Synlogic Appoints Dr. Michael Burgess to its Board of Directors January 9, 2020 Synlogic Outlines Upcoming Milestones for Clinical Programs and Unveils New Preclinical Pipeline Programs December 11, 2019 Synlogic Bridging Study Data with Solid Oral Formulation of SYNB1618, a Synthetic Biotic Approach to Treat Phenylketonuria, Demonstrate Improved Tolerability over Early Liquid Formulation and Guide to Next Stage of Clinical Development November 25, 2019 Synlogic to Webcast Presentation at the Piper Jaffray 31st Annual Healthcare Conference November 12, 2019 Synlogic Provides Program and Business Update and Reports Third Quarter 2019 Financial Results Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 1 - 10 of 103 Email Alerts Contact IR RSS Feeds Print Page Email Page
Items Per Page 102550 Year None2020201920182017201620152014 March 30, 2020 Synlogic Provides Summary of Impact of COVID-19 on Clinical Program Progress and Operational Activities March 12, 2020 Synlogic Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update March 11, 2020 Synlogic to Present at Chardan's Virtual Microbiome Medicines Summit March 5, 2020 Synlogic Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast February 18, 2020 Synlogic Announces Participation in Upcoming Investor Conferences January 30, 2020 Synlogic Appoints Dr. Michael Burgess to its Board of Directors January 9, 2020 Synlogic Outlines Upcoming Milestones for Clinical Programs and Unveils New Preclinical Pipeline Programs December 11, 2019 Synlogic Bridging Study Data with Solid Oral Formulation of SYNB1618, a Synthetic Biotic Approach to Treat Phenylketonuria, Demonstrate Improved Tolerability over Early Liquid Formulation and Guide to Next Stage of Clinical Development November 25, 2019 Synlogic to Webcast Presentation at the Piper Jaffray 31st Annual Healthcare Conference November 12, 2019 Synlogic Provides Program and Business Update and Reports Third Quarter 2019 Financial Results Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 1 - 10 of 103
March 30, 2020 Synlogic Provides Summary of Impact of COVID-19 on Clinical Program Progress and Operational Activities
March 12, 2020 Synlogic Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
January 9, 2020 Synlogic Outlines Upcoming Milestones for Clinical Programs and Unveils New Preclinical Pipeline Programs
December 11, 2019 Synlogic Bridging Study Data with Solid Oral Formulation of SYNB1618, a Synthetic Biotic Approach to Treat Phenylketonuria, Demonstrate Improved Tolerability over Early Liquid Formulation and Guide to Next Stage of Clinical Development
November 25, 2019 Synlogic to Webcast Presentation at the Piper Jaffray 31st Annual Healthcare Conference
November 12, 2019 Synlogic Provides Program and Business Update and Reports Third Quarter 2019 Financial Results